NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201505-05-2023
05-05-2023
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201503-05-2023
NOVARTIS INDIA LTD. - 500672 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company NOVARTIS INDIA LTD. 2 CIN NO. L24200MH1947PLC006104 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, FY 2023-2024, FY 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* N.A. 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* N.A. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2020-21, FY 2021-22, FY 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Nikhil MalpaniDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Shilpa Joshi Designation : -Whole Time Director and...29-04-2023
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201525-04-2023
NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Pursuant To Regulations 40(9) & (10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Compliance Certificate pursuant to Regulations 40(9) & (10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201519-04-2023
NOVARTIS INDIA LTD. - 500672 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyNOVARTIS INDIA LTD. 2CIN NO.L24200MH1947PLC006104 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY - 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nikhil Malpani Designation: Company Secretary and Compliance Officer EmailId: nikhil.malpani@novartis.com Name of the Chief Financial Officer: Shilpa Joshi Designation: Whole Time Director and Chief Financial Officer EmailId: shilpa.joshi@novartis.com Date: 19/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.19-04-2023
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201514-04-2023
NOVARTIS INDIA LTD. - 500672 - Compliances For The Financial Year Ended March 31, 2023
Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended March 31, 202314-04-2023
Novartis eyes rare disease market in India, runs 17 clinical programs
In 2022, Novartis invested around $10 billion in overall research and development (R&D) and has already secured 23 approvals in the United States, European Union, China and Japan for new medicines and new indications for existing medicines.12-04-2023
NOVARTIS INDIA LTD. - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 202311-04-2023